Compare LEDS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | AKTX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 11.5M |
| IPO Year | 2010 | 2014 |
| Metric | LEDS | AKTX |
|---|---|---|
| Price | $1.23 | $0.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | 10.5K | ★ 341.3K |
| Earning Date | 04-09-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,009,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.11 | $0.13 |
| 52 Week High | $3.37 | $1.58 |
| Indicator | LEDS | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 24.57 |
| Support Level | N/A | N/A |
| Resistance Level | $2.02 | $0.27 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 26.67 | 3.44 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.